Clinical Trial Update: Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating intravitreal ranibizumab (Lucentis) for neovascular glaucoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Glaucoma

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: LEANDRO CABRAL ZACHARIAS | Conditions: Glaucoma, Neovascular, Ranibizumab | Phase 3 | Status: UNKNOWN